Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw unusually-strong trading volume on Friday . Approximately 2,270,491 shares changed hands during mid-day trading, an increase of 2% from the previous session’s volume of 2,223,138 shares.The stock last traded at $91.66 and had previously closed at $88.16.

BMRN has been the topic of several research analyst reports. Piper Jaffray Cos. restated an “overweight” rating and issued a $107.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, March 28th. Credit Suisse Group AG restated a “buy” rating and issued a $114.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, April 29th. Barclays PLC restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, June 16th. Wedbush restated a “neutral” rating and issued a $108.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, April 19th. Finally, BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, April 7th. They issued an “outperform” rating and a $99.00 price target on the stock. Three analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical currently has an average rating of “Buy” and an average target price of $123.82.

The firm’s 50 day moving average price is $84.02 and its 200-day moving average price is $84.40. The company’s market capitalization is $14.85 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, April 28th. The company reported ($0.53) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.85) by $0.32. During the same period in the previous year, the firm earned ($0.43) earnings per share. The company had revenue of $236.70 million for the quarter, compared to analysts’ expectations of $240.21 million. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.02) EPS for the current year.

In related news, EVP Jeffrey Robert Ajer sold 415 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $86.03, for a total transaction of $35,702.45. Following the sale, the executive vice president now owns 63,487 shares of the company’s stock, valued at approximately $5,461,786.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jean Jacques Bienaime sold 50,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $80.15, for a total value of $4,007,500.00. Following the sale, the chief executive officer now directly owns 390,156 shares in the company, valued at approximately $31,271,003.40. The disclosure for this sale can be found here.

A number of hedge funds have modified their holdings of the stock. Columbus Circle Investors increased its stake in shares of BioMarin Pharmaceutical by 16.6% in the fourth quarter. Columbus Circle Investors now owns 263,999 shares of the company’s stock valued at $27,657,000 after buying an additional 37,615 shares during the period. Mizuho Trust & Banking Co. Ltd. increased its stake in shares of BioMarin Pharmaceutical by 0.3% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 233,477 shares of the company’s stock valued at $24,695,000 after buying an additional 802 shares during the period. Vanguard Group Inc. increased its stake in shares of BioMarin Pharmaceutical by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 11,195,877 shares of the company’s stock valued at $1,172,880,000 after buying an additional 355,727 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of BioMarin Pharmaceutical by 5.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 153,926 shares of the company’s stock valued at $16,127,000 after buying an additional 7,529 shares during the period. Finally, TD Asset Management Inc. increased its stake in shares of BioMarin Pharmaceutical by 0.3% in the fourth quarter. TD Asset Management Inc. now owns 105,383 shares of the company’s stock valued at $11,040,000 after buying an additional 310 shares during the period.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.